The FDA has requested five large clinical trials to evaluate fixed-dose ICS–LABA products with the primary outcome of life-threatening asthma exacerbation or death. The results will not be ...

Previous guidelines recommended the use of maintenance inhalers such as those that combine ICS and a long-acting beta agonist (LABA), generally used twice a day, in addition to short-acting rescue ...

a triple-therapy inhaler containing an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta-agonist (LABA), was found to offer comparable or incremental ...